Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

NDAQ:ALNY - Post by User

Alnylam Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(303)
•••

Post by whytestockson Feb 15, 2024 8:15pm

67 Views

Post# 35883253

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year

News; $ALNY Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity− Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − Company Announces Updated Statistical Analysis Plan and Timing for HELIOS-B Phase 3 Study of ...ALNY - Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

<< Previous

Bullboard Posts

Next >>

What is the 'kiddie tax' when gifting stock?